CONMED (CNMD)
(Delayed Data from NYSE)
$74.76 USD
-0.88 (-1.16%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $74.82 +0.06 (0.08%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.76 USD
-0.88 (-1.16%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $74.82 +0.06 (0.08%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Is a Beat Likely for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Is a Beat Likely for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at both Dental and Animal Health segments.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.
Conmed (CNMD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 5.06% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
Patterson Companies (PDCO) Q4 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2023 results reflect robust improvement in Dental Equipment sales, Value-added services and Animal Health segment.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.
Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe
by Zacks Equity Research
Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.
Orthofix (OFIX) Advances in ALIF Procedure With New Launch
by Zacks Equity Research
Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.
Quest Diagnostics (DGX) Partners to Offer New Testing Service
by Zacks Equity Research
Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.
Here's Why You Should Buy Boston Scientific (BSX) Stock
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.
Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice
by Zacks Equity Research
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?
by Zacks Equity Research
The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.
Hologic (HOLX) Gains From Core Businesses' Growth, Innovation
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.
IDEXX (IDXX) Launches First Veterinary Diagnostic Test
by Zacks Equity Research
IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.
Masimo (MASI) Inks Deals for Patient Monitoring Technologies
by Zacks Equity Research
Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.
NextGen (NXGN) Expands Partnership With Large Urology Group
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solution, Enterprise EHR, is selected by Associated Urologists of North Carolina to create an integrated platform, especially for urology-specific workflows.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.